The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Hims & Hers Health Inc shares valued at $1,786,982 were purchased by Melissa Baird on Jun 04 ’25. At $53.61 per share, Melissa Baird acquired 33,333 shares.
Also, Okupe Oluyemi sold 11,581 shares, netting a total of over 613,537 in proceeds. Following the sale of shares at $52.98 each, the insider now holds 39,153 shares.
Before that, Boughton Soleil had sold 3,233 shares from its account. In a trade valued at $180,628, the Chief Legal Officer traded Hims & Hers Health Inc shares for $55.87 each. Upon closing the transaction, the insider’s holdings decreased to 3,233 shares, worth approximately $8.21 million.
As published in a research note from Needham on June 04, 2025, Hims & Hers Health Inc [HIMS] has been retained to a Buy and the price target has been revised to $65. Analysts at TD Cowen downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in late April. As of February 18, 2025, Morgan Stanley has decreased its “an Overweight” rating to a “an Equal-weight” for HIMS. Earlier on January 10, 2025, Citigroup downgraded its rating. Their new recommendation was “a Sell” for HIMS stock which previously was a “a Neutral”.
Analyzing HIMS Stock Performance
During the last five days, there has been a surge of approximately 0.51%. Over the course of the year, Hims & Hers Health Inc shares have jumped approximately 121.71%. Shares of the company reached a 52-week high of $72.98 on 02/19/25 and a 52-week low of $23.97 on 04/04/25.
Support And Resistance Levels for Hims & Hers Health Inc (HIMS)
According to the 24-hour chart, there is a support level at 51.18, which, if violated, would cause prices to drop to 48.74. In the upper region, resistance lies at 57.67. The next price resistance is at 61.72. RSI (Relative Strength Index) is 54.50 on the 14-day chart, showing neutral technical sentiment.
